Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations

This 2026 narrative review synthesises a decade of evidence on how common non-antibiotic medications — proton pump inhibitors (PPIs), metformin, NSAIDs, statins, SGLT2 inhibitors, and oral iron — reshape the community of microbes living in our gut. The gut microbiome is not a passive bystander: it can activate or inactivate drugs, alter how much reaches the bloodstream, and generate metabolites that feedback onto the body. By screening four major databases and applying strict inclusion criteria (human studies, molecular microbiome profiling, at least 20 participants, and a control arm), the authors distilled 20 high-quality studies from an initial 68. The headline messages are that PPIs effectively 'oralise' the lower gut — letting mouth-origin bacteria colonise the intestine — raising risks of Clostridioides difficile infection and small-intestinal bacterial overgrowth (SIBO). Metformin, by contrast, actively promotes beneficial microbes like Akkermansia muciniphila, and this microbial shift appears to contribute meaningfully to the drug's glucose-lowering effect. Oral iron consistently handed a competitive advantage to potentially harmful Enterobacteriaceae while crowding out beneficial commensals. The review argues that microbiome profiling should be integrated into pharmacovigilance and that 'pharmacomicrobiomics' — understanding how drugs reshape microbial communities — is now clinically relevant, not just experimental.

• PPIs significantly remodelled gut microbiota with enrichment of oral-origin taxa ('oralisation of the gut'), and this shift was associated with increased risk of Clostridioides difficile infection and small-intestinal bacterial overgrowth (SIBO).
• Metformin enriched Akkermansia muciniphila and butyrate-producing bacteria; the authors characterise this microbial remodelling as causally contributing to metformin's glycaemic efficacy, not merely a correlational side-effect.
• NSAIDs compromised gut barrier integrity, and co-prescription with PPIs produced synergistic dysbiosis — a clinically important drug-drug-microbiome interaction.
• Statins correlated with reduced prevalence of the pro-inflammatory Bact2 enterotype, suggesting a microbiome-mediated component to their anti-inflammatory benefit.
• Oral iron consistently enriched Enterobacteriaceae at the expense of beneficial commensals across studies, raising concerns about routine iron supplementation in populations with already-compromised microbiota.
• SGLT2 inhibitor data were discordant across included studies, precluding firm conclusions about their net pharmacomicrobiomic effect.
• Of 68 eligible studies identified, only 20 (29%) met criteria for the evidence tables, highlighting the methodological heterogeneity and quality gaps still prevalent in human pharmacomicrobiomics research.

This is a narrative review conducted following PRISMA 2020 reporting principles but without PROSPERO pre-registration. Four databases — PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library — were searched for publications from January 2015 to December 2024. Inclusion in evidence tables required clinical human studies with molecular microbiota characterisation (16S rRNA or shotgun metagenomics), a minimum of 20 participants, and a control arm; 20 of 68 eligible studies met these criteria. Preclinical data were incorporated into mechanistic synthesis sections but were not included in the formal evidence tables.

As a narrative review without pre-registration or quantitative meta-analysis, the findings are vulnerable to selection bias and cannot provide pooled effect sizes or formal assessments of heterogeneity. The restriction to studies published after January 2015 may have excluded earlier foundational human data. Mechanistic conclusions — particularly around causal contribution of microbiota shifts to drug efficacy (e.g., metformin-Akkermansia axis) — are extrapolated from observational associations and preclinical models rather than interventional microbiome-manipulation trials. The next critical experiment would be randomised controlled trials that stratify patients by baseline microbiome enterotype before drug assignment, with longitudinal metagenomics and paired pharmacokinetic sampling to disentangle microbiome-driven variance in drug response from host genetics and diet.

This review directly extends [§156], which examines the role of Akkermansia muciniphila in a specific clinical condition, by showing that the same taxon is pharmacologically modifiable — metformin reliably enriches it — thereby connecting drug exposure to mucosal and metabolic outcomes. It parallels [§145], which investigates how green tea polyphenol-iron oxide nanoparticles modulate gut microbiota and metabolic pathways, since both articles frame non-antibiotic substances as potent microbial modulators with downstream metabolic consequences, though the current review covers conventional pharmaceuticals at population scale. The oral-iron findings — consistent Enterobacteriaceae enrichment at the expense of commensals — sit in productive tension with [§155] (Saccharomyces boulardii and intestinal barrier function), raising the question of whether probiotic co-administration could mitigate iron-driven dysbiosis. The review's mechanistic treatment of NSAID-mediated barrier disruption and synergistic dysbiosis under PPI co-prescription also contextualises findings from [§154] on dietary FODMAP restriction and functional gastrointestinal disorders, where barrier integrity and luminal microbial composition are equally central variables.

• Role of Akkermansia Muciniphila in Acne Vulgaris
  Directly complementary: this article isolates Akkermansia muciniphila's role in a specific disease context, while the review under enrichment establishes that metformin pharmacologically drives A. muciniphila enrichment — reading both clarifies whether the taxon's benefits are disease-specific or broadly applicable.
• Green tea polyphenol-iron oxide chitosan nanoparticles modulate gut microbiota and regulate metabolic pathways
  Both examine how non-antibiotic substances remodel gut microbiota and regulate metabolic pathways, but [id=145] uses nanomaterial delivery of polyphenols rather than conventional drugs — comparing the two reveals whether microbial shifts depend on the substance class or on shared downstream metabolic targets.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii's effects on intestinal barrier function offer a potential therapeutic counterpoint to the NSAID- and PPI-driven barrier compromise described in the review, making the two articles jointly useful for designing microbiome-protective co-prescription strategies.
• Mechanism of FODMAP Restriction on FGID Patients
  The FODMAP restriction review addresses luminal fermentation, microbial composition, and gut symptom outcomes — an important dietary-intervention comparator for understanding whether the dysbiotic effects of drugs like NSAIDs and oral iron can be partially offset by dietary modification.
• Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
  This probiotic intervention study in antibiotic-exposed infants examines microbiome restoration, offering a developmental and prophylactic angle that complements the review's focus on drug-induced adult dysbiosis and raises the question of whether probiotic co-prescription could mitigate pharmacomicrobiomic harms across the lifespan.